Overview

* Halozyme Q2 2025 rev grows 41% yr/yr, beating analyst expectations, per LSEG data

* Adjusted EPS for Q2 2025 beats consensus, rising 69% yr/yr, per LSEG data

* Co raises 2025 guidance, announces third $250 mln share repurchase tranche

Outlook

* Halozyme raises 2025 revenue guidance to $1,275 mln-$1,355 mln

* Company expects 2025 royalty revenue of $825 mln-$860 mln

* Halozyme forecasts 2025 adjusted EBITDA of $865 mln-$915 mln

* Company sees 2025 non-GAAP EPS at $6.00-$6.40

Result Drivers

* ROYALTY REVENUE - 65% increase in royalty revenue driven by blockbuster therapies DARZALEX SC, Phesgo, and VYVGART Hytrulo

* REGULATORY APPROVALS - Multiple approvals, including RYBREVANT SC in Europe and VYVGART Hytrulo for CIDP, expected to boost future growth

* ENHANZE TECHNOLOGY - High-margin royalty streams and global demand for ENHANZE technology cited as key growth drivers

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $326 mln $285.90

Revenue mln (7

Analysts

)

Q2 Beat $1.54 $1.27 (5

Adjusted Analysts

EPS )

Q2 EPS $1.33

Q2 Net $165 mln

Income

Q2 $202.40

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Halozyme Therapeutics Inc ( HALO ) is $68.50, about 12.4% above its August 4 closing price of $59.99

* The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)